We're developing a broad portfolio that has the potential to meaningfully improve millions of lives.

Vaxxine Program (Target)

Stages

Indications

Preclinical

IND

Phase I

Phase II

Phase III

Marketed

NEURODEGENERATION

Preclinical

IND

Phase I

Phase II

Phase III

Marketed

UB-311

Alzheimer’s

UB-312

Parkinson’s, DLB, MSA

Tau

Alzheimer’s, Other

NEXT WAVE
CHRONIC

Preclinical

IND

Phase I

Phase II

Phase III

Marketed

UB-313

Migraine

PCSK9

Hypercholesterolemia

INFECTIOUS
DISEASE

Preclinical

IND

Phase I

Phase II

Phase III

Marketed

UB-612

Covid-19